methyl 2-(morpholin-4-yl)pyridine-4-carboxylate | 83728-67-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: methyl 2-(morpholin-4-yl)pyridine-4-carboxylate
• 英文别名: Methyl 4-(morpholin-4-YL)pyridine-2-carboxylate；methyl 4-morpholin-4-ylpyridine-2-carboxylate
• CAS: 83728-67-0
• 化学式: C₁₁H₁₄N₂O₃
• 分子量: 222.244
• InChiKey: GCQFDBHRYFQDMQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  51.7
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  methyl 2-(morpholin-4-yl)pyridine-4-carboxylate 在 盐酸 、 水 作用下， 反应 7.0h， 生成 4-(4-吗啉)-甲酸吡啶
  参考文献：
  名称：

  [EN] PROTEIN KINASE INHIBITORS AND METHODS OF TREATMENT
  [FR] INHIBITEUR DE PROTÉINE KINASES ET MÉTHODES DE TRAITEMENT

  摘要：

  本发明涉及化合物的化学式(I)以及其使用和制备方法。具体而言，本发明涉及基于取代的吡唑并[3,4-d]嘧啶的化合物，可用于治疗增殖性疾病，这些化合物在治疗方法中的使用以及药物的制造，以及含有这些化合物的组合物。

  公开号：

  WO2012003544A1
• 作为产物：
  描述：

  4-(4-吗啉)-甲酸吡啶 在 氯化亚砜 作用下， 反应 0.5h， 生成 methyl 2-(morpholin-4-yl)pyridine-4-carboxylate
  参考文献：
  名称：

  Morkved, Eva H.; Cronyn, Marshall W., Acta chemica Scandinavica. Series B: Organic chemistry and biochemistry, 1982, vol. 36, # 6, p. 381 - 388

  摘要：

  DOI：

文献信息

• Lead Optimization of 4-Acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A_2A Adenosine Receptor Antagonists for the Treatment of Parkinson’s Disease
  作者：Xiaohu Zhang、John E. Tellew、Zhiyong Luo、Manisha Moorjani、Emily Lin、Marion C. Lanier、Yongsheng Chen、John P. Williams、John Saunders、Sandra M. Lechner、Stacy Markison、Tanya Joswig、Robert Petroski、Jaime Piercey、William Kargo、Siobhan Malany、Mark Santos、Raymond S. Gross、Jenny Wen、Kayvon Jalali、Zhihong O’Brien、Carol E. Stotz、María I. Crespo、José-Luis Díaz、Deborah H. Slee

  DOI：10.1021/jm800851u

  日期：2008.11.27

  4-Acetylamino-2-(3,5-dimethylpyrazol-1-yl)-pyrimidines bearing substituted pyridyl groups as C-6 substituents were prepared as selective adenosine hA(2A) receptor antagonists for the treatment of Parkinson's disease. The 5-methoxy-3-pyridyl derivative 6g (hA(2A) K-i 2.3 nM, hA(1) K-i 190 nM) was orally active at 3 mg/kg in a rat HIC model but exposure was poor in nonrodent species, presumably due to poor aqueous solubility. Follow-on compound 16a (hA(2A) K-i 0.83 nM, hA(1) K-i 130 nM), bearing a 6-(morpholin-4-yl)-2-pyridyl substituent at C-6, had improved solubility and was orally efficacious (3 mg/kg, HIC) but showed time-dependent cytochrome P450 3A4 inhibition, possibly related to morpholine ring metabolism. Compound 16j (hA(2A) K-i 0.44 nM, hA(1) K-i 80 nM), bearing a 6-(4-methoxypiperidin-1-yl)-2-pyridyl substituent at C-6, was sparingly soluble but had good oral exposure in rodent and nonrodent species, had no cytochrome P450 or human ether-a-go-go related gene channel issues, and was orally efficacious at 1 mg/kg in HIC and at 3 mg/kg for potentiation Of L-dopa-induced contralateral rotations in 6-hydroxydopamine-lesioned rats.
• MORKVED, E. H.;CRONYN, M. W., ACTA CHEM. SCAND., 1982, 36, N 6, 381-388
  作者：MORKVED, E. H.、CRONYN, M. W.

  DOI：——

  日期：——
• [EN] PROTEIN KINASE INHIBITORS AND METHODS OF TREATMENT<br/>[FR] INHIBITEUR DE PROTÉINE KINASES ET MÉTHODES DE TRAITEMENT
  申请人：INST MEDICAL W & E HALL

  公开号：WO2012003544A1

  公开（公告）日：2012-01-12

  The present invention relates to chemical compounds of formula (I) and methods for their use and preparation. In particular, the invention relates to substituted pyrazolo[3,4-d]pyrimidine based compounds which can be used in treating proliferative disorders, use of these compounds in methods of therapy and the manufacture of medicaments as well as compositions containing these compounds.

  本发明涉及化合物的化学式(I)以及其使用和制备方法。具体而言，本发明涉及基于取代的吡唑并[3,4-d]嘧啶的化合物，可用于治疗增殖性疾病，这些化合物在治疗方法中的使用以及药物的制造，以及含有这些化合物的组合物。
• Morkved, Eva H.; Cronyn, Marshall W., Acta chemica Scandinavica. Series B: Organic chemistry and biochemistry, 1982, vol. 36, # 6, p. 381 - 388
  作者：Morkved, Eva H.、Cronyn, Marshall W.

  DOI：——

  日期：——